Tag: Ambrx
FDA Grants Fast Track Designation for ARX517 in Metastatic Castration-Resistant Prostate...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARX517, a proprietary anti-PSMA antibody-drug conjugate (ADC) investigational being therapy developed by Ambrx for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor.
Ambrx and Novocodex to Jointly Develop and Commercialize 2nd Antibody-drug Conjugate
Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and Ambrx, a privately-held clinical stage biopharmaceutical company, have confirmed that the companies will jointly develop and...
WuXi Biologics Opens New Facility to Supports Novocodex ADC Manufacturing
Earlier this month China-based Contract Research Organization (CRO) WuXi Biologics started commercial production at the company's new Current Good Manufacturing Practice (cGMP)-approved DP3 bulk...
Ambrx and MabSpace Biosciences Jointly Develop New Antibody Drug Conjugates
San Diego based biotech company Ambrx and MabSpace Biosciences, a biotechnology company focusing on discovery and development antibody therapeutics using its immune tolerance breaking...
ARX788 First-In-Human Phase I Clinical trial in HER2 cancer patients
A First-In-Human phase I clinical trial with ARX788, an site-specific antibody-drug conjugate being developed by Ambrx® and Zhejiang Medicine has been initiated as a multicenter...
